Infant Formula Manufacturers Decide Whether to Inform FDA About Possible Harm
Truthout is a vital news source and a living history of political struggle. If you think our work is valuable, support us with a donation of any size.
In September 2016, a distraught mother sent infant formula maker Mead Johnson a message:
“REMOVE ME FROM YOUR LIST!!!! DO NOT EMAIL OR MAIL ME ANY MORE!
“It is because of your animal based pre-term artificial baby food crap that you peddle to hospital NICU’s that my son is dead from NEC.”
The mother was referring to neonatal intensive care units and necrotizing enterocolitis, an often fatal condition in which intestinal tissue can die and allow infection to spread through the body of an infant born prematurely.
In an internal memo, Mead Johnson cited its “extensive quality and safety checks” and concluded there was “not a reasonable possibility” that the formula caused the baby’s death. “No further investigation is needed. This file can be closed,” the memo said.
FDA Blocks Studies Showing Safety of COVID, Shingles Vaccines
And with that decision, the company narrowed the chance that the mother’s anguish could draw attention to any danger the formula might pose to other infants.
The mother’s email and the company’s memo assessing it were used as evidence in the court cases Watson v. Mead Johnson and Whitfield v. St. Louis Children’s Hospital, et al.
When doctors, hospitals, parents, or others alert manufacturers that babies got sick or died while receiving infant formula, what happens next is left largely to manufacturers such as Abbott Laboratories and Mead Johnson Nutrition, giants of the industry.
Mead Johnson’s handling of the mother’s email showed how that can play out.
Under federal rules, if a complaint about an infant formula — such as a report of an adverse event — shows a possible health hazard, the company must investigate.
But it doesn’t always have to inform the government agency that oversees the safety of infant formula.
A company must complete an investigation and notify the Food and Drug Administration within 15 days only if it finds “a reasonable possibility of a causal relationship between the consumption of an infant formula and an infant’s death.”
If that happened even once over more than a quarter century, the FDA could find no record of it, according to information obtained through public records requests.
Under the Freedom of Information Act, KFF Health News asked the FDA for all notifications that manufacturers of infant formula sent the agency per the regulatory requirement since Jan. 1, 2020. The agency’s Human Foods Program “did not receive any,” Kimberly Jones, a government information specialist at the FDA, responded in March.
KFF Health News then asked the FDA to go back decades further — to Jan. 1, 2000. “After a diligent search of our files, we did not locate any responsive records,” Jones wrote on May 5.
The FDA’s search results were consistent with court testimony.
John Wallingford, a paid expert witness for Abbott, testified in a Missouri court in October 2024 that Abbott had never reported a single death under any regulation for preterm infant formula.
Wallingford clarified that he was not referring to adverse events in clinical trials, which are studies used for research and development and are subject to different procedures. Abbott informed the FDA about adverse events that occurred during a clinical trial, Wallingford testified.
Christina Valentine testified in a 2024 deposition that she never sent the FDA a report of death from NEC during her seven years as Mead Johnson’s medical director for North America. In the deposition, used in the Whitfield case, she said she never concluded there was a reasonable possibility that an infant’s death from NEC might have been related to a Mead Johnson product.
As medical director for North America, she was responsible for signing off on those determinations, she testified in the Watson trial.
In the deposition, Valentine said she wasn’t sure whether anyone else at the company sent a death report to the FDA.
In late May and mid-June, Mead Johnson spokesperson Jen O’Neill added to the picture.
“Where there is a physician report that includes an opinion that one of our products caused NEC in a preterm infant, we have treated that as a ‘reasonable possibility of a causal relationship,’ and we submitted an adverse event report to the FDA,” she wrote.
“These physician reports were generally made by plaintiffs’ paid experts, with which we disagree,” she wrote.
O’Neill left unclear whether events Mead Johnson reported to the FDA were raised in lawsuits and, if so, whether the company reported them to the FDA before they surfaced in litigation.
Asked repeatedly when Mead Johnson filed the reports, O’Neill didn’t say.
It’s unclear why the FDA found no record of them.
Nor would O’Neill say whether the company submitted one related to the distraught mother’s September 2016 complaint.
That mother’s name wasn’t publicly disclosed in the court record containing her complaint.
“[P]rior to the current litigation, we received very few reports relating to our products and NEC and even fewer for which our investigation uncovered any evidence supporting a reasonable possibility of a causal relationship,” O’Neill wrote.
Industry personnel have reacted to some complaints with circular reasoning, as shown by court records from the Watson, Whitfield, and Gill v. Abbott Laboratories cases. Company personnel didn’t think their products caused harm, and they didn’t view new cases as evidence of harm, records show.
“Reprehensible” Conduct
About 2,300 newborns died of necrotizing enterocolitis in the United States from 2017 through 2023, the equivalent of almost one per day, according to a KFF Health News analysis of a government data set for those years. The database doesn’t attempt to explain what caused those babies to develop NEC, and it doesn’t count babies who survived NEC.
A wave of lawsuits has alleged that infant formula made........
